CELG-RI
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$0.11
+0.00%Year over year
Reported trailing growth
- Revenue
- +3.1%
- EBITDA
- +12.8%
- EBIT
- +27.9%
- EPS
- +83.1%
- Free cash flow
- -21.5%
- Operating cash flow
- -19.6%
Forward estimates
Based on analyst estimates
- Revenue
- -3.0%
- EBITDA
- +7.6%
- EPS
- +36.6%
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- -7.2%
- EBIT
- +18.4%
- Net income
- +3.7%
- EPS
- +5.3%
- Free cash flow
- +2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026